In Brief: Amgen consensus interferon
Executive Summary
Amgen consensus interferon: Yamanouchi licenses rights to market consensus interferon in all markets except North America. The Japanese firm paid Amgen $15 mil. for the license and could make milestone payments up to "several times that amount," Amgen says. The biotech also will receive royalties on product sales. Amgen plans to market consensus interferon in the U.S. and Canada under the Infergen trade name; a PLA is pending in the U.S. for treatment of hepatitis C...